The Role of Autophagy in Pancreatic Cancer—Recent Advances
Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest cancers with a 5-year survival rate of only 9%, despite ongoing efforts to improve treatment. This dismal prognosis is due to the difficulty of early stage diagnosis, drug resistance, and likelihood of metastasis development. It is...
Main Authors: | Maria New, Sharon Tooze |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2019-12-01
|
Series: | Biology |
Subjects: | |
Online Access: | https://www.mdpi.com/2079-7737/9/1/7 |
Similar Items
-
Therapeutic Aspects and Molecular Targets of Autophagy to Control Pancreatic Cancer Management
by: Md. Ataur Rahman, et al.
Published: (2022-06-01) -
Inhibition of endoplasmic-reticulum-stress-mediated autophagy enhances the effectiveness of chemotherapeutics on pancreatic cancer
by: Prakash C. Thakur, et al.
Published: (2018-07-01) -
Long Non-Coding RNAs and Metabolic Rewiring in Pancreatic Cancer
by: Bruna Dalmasso, et al.
Published: (2023-07-01) -
Perturbation of Autophagy by a Beclin 1-Targeting Stapled Peptide Induces Mitochondria Stress and Inhibits Proliferation of Pancreatic Cancer Cells
by: Na Li, et al.
Published: (2023-02-01) -
Repurposing econazole as a pharmacological autophagy inhibitor to treat pancreatic ductal adenocarcinoma
by: Ningna Weng, et al.
Published: (2022-07-01)